Asia-Pacific indapamide market is estimated to grow significantly at a CAGR of around 3.8% during the forecast period owing to the increasing prevalence of chronic disorders, including hypertension, CVD, and diabetes. The rising incidences of these diseases have been reported in several countries of Asia-Pacific, including China, India, and Singapore. For instance, in India, one in five young adults has high blood pressure, according to the data presented at the 70th Annual Conference of the Cardiological Society of India (CSI) held from November 22nd- 25th 2018. This equals to nearly 80 million adults, which is a significant proportion than the entire UK population. The risk factors for high blood pressure in the country were smoking, tobacco chewing, diabetes mellitus, and high cholesterol. This, in turn, increased the need for hypertension treatment in the region and further encourages the market growth.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-indapamide-market
The Asia-Pacific indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
The companies which are contributing to the growth of the Asia-Pacific indapamide market include Glenmark Pharmaceuticals Ltd, Shandong Yinfeida Pharmaceutical Co., Ltd., Suzhou Lixin Pharmaceutical Co., Ltd., Merck KGaA, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Asia-Pacific Indapamide Market Segmentation
By Product
- 25 MG
- 5 MG
By Application
- High Blood Pressure
- Heart Failure
- Others
A full report of Asia-Pacific Indapamide Market available @ https://www.omrglobal.com/industry-reports/asia-pacific-indapamide-market
Regional Analysis
- China
- India
- Japan
- Rest of Asia-Pacific
Company Profiles
- ANI Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Ltd.
- Merck KGaA
- Sandoz International GmbH
- Sanofi S.A.
- Shandong Yinfeida Pharmaceutical Co., Ltd.
- Supra Chemicals
- Suzhou Lixin Pharmaceutical Co., Ltd.
- Taj Pharmaceuticals Ltd.
- Torrent Pharmaceuticals Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research